| Cormorant Asset Management, LP | ▼ Sell | Open Market | 109,331 | $9.8M | 4/28/2026 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 184,331 | $4.0M | 11/4/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 7,150 | $172K | 10/16/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 39,743 | $923K | 10/16/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 3,107 | $78K | 10/16/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 238,097 | $1.1M | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 63,173 | $374K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 33,343 | $214K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 8,900 | $65K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 2,600 | $23K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 2,700 | $25K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 19,169 | $225K | 10/15/2024 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 4,609 | $57K | 10/15/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Bright Minds Biosciences Gains Attention from Wolfe Research
Wolfe Research has started coverage of Bright Minds Biosciences, giving it an outperform rating and a price target of $150. The coverage comes as a Canadian biotech stock that is trading significantly below its fair value, up to 93% below, according to a recent Yahoo report. The new rating highlights the company’s potential relative to its peers. Investors are noting the price target in the context of the stock’s 52‑week range of $68.02 to $170.00.
Bright Minds Biosciences Gains Attention from Wolfe Research. Wolfe Research has started coverage of Bright Minds Biosciences, giving it an outperform rating and a price target of $150. The coverage comes as a Canadian biotech stock that is trading significantly below its fair value, up to 93% below, according to a recent Yahoo report. The new rating highlights the company’s potential relative to its peers. Investors are noting the price target in the context of the stock’s 52‑week range of $68.02 to $170.00.